Royal Bank of Canada
AAPG

Royal Bank of Canada’s Ascentage Pharma AAPG Stock Holding History

Royal Bank of Canada’s Portfolio AAPG Stock Details AAPG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Hold
6
– – ﹤0.01% 7857
2025
Q4 		$0 Buy
+6
New +$196 ﹤0.01% 7795
2025
Q3 		– Sell
-6
Closed – – 7653
2025
Q2 		$0 Buy
+6
New +$158 ﹤0.01% 7462

Other funds holding AAPG

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
XC
XY Capital Central, Hong Kong $101M AUM 1.14% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.72% 1-Year Est. Return

Royal Bank of Canada's AAPG Position: Q1 2026 in Review

Royal Bank of Canada held its Ascentage Pharma (AAPG) position steady in Q1 2026 at 6 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7857.

Royal Bank of Canada first reported a position in AAPG in Q2 2025 and has held it in 3 quarters since. 7 funds tracked by Wall St. Rank hold AAPG as of Q1 2026.

  • Royal Bank of Canada held 6 shares of Ascentage Pharma worth $0 as of Q1 2026.
  • Royal Bank of Canada left its Ascentage Pharma share count unchanged in Q1 2026.
  • Ascentage Pharma made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #7857 holding.
  • Royal Bank of Canada first reported a position in Ascentage Pharma in Q2 2025 and has held it in 3 quarters since.
  • 7 funds tracked by Wall St. Rank held Ascentage Pharma as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.